FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma

Figure 5

FCGR2A transcription in subgroups of patients with HNSC, stratified based on gender, race, and other criteria (UALCAN). (a) Relative expression of FCGR2A in normal and HPV-positive and HPV-negative HNSC samples. (b) Relative expression of FCGR2A in normal and HNSC patients with grade 1, 2, 3, and 4 tumors. (c) Relative expression of FCGR2A in normal or HNSC patients with stage N1, N2, N3, and N4. (d) Relative expression of FCGR2A in normal patients or in HNSC patients at stages 1, 2, 3, and 4. (e) Relative expression of FCGR2A in normal, Caucasian, African-American, and Asian HNSC patients. (f) Relative expression of FCGR2A in normal, male, and female HNSC patients. The central marker was the median; the edges of the box were the 25th and 75th percentiles. The -test was used to estimate the significance of difference in gene expression levels between groups. ; ; .

(a)

(b)

(c)

(d)

(e)

(f)